Resumen

TOMASZ ROS, LESZEK. La evaluación de los efectos terapéuticos de Paroxetina en el síndrome depresivo endógeno. AVFT [online]. 2006, vol.25, n.2, pp.72-77. ISSN 0798-0264.

Summary The assessment of therapeutic effects of Paroxetyna in major depression syndrome using the psychological scales and patients’ psychiatric treatment. The group chosen for the study consisted of 99 patients treated with Paroxetyna due to a major depression syndrome. The control group consisted of 98 patients treated with Sulpiride due to a major depression syndrome. Data for the study were taken from the diseases history of the persons. All patients were carefully diagnosed according to 24 points Hamilton Depression Evaluation Scale, Beck Depression Self-Assessment Inventory and Montgomery-Asberg Scale. The effects of the treatment were assessed using the those scales and patients’ psychiatric treatment. Generally good effects of the treatment were observed for approximately 80% off all patients treated with Paroxetyna. Average results after treatment decreased from 46.2 points to 17.4 points in Hamilton Depression Evaluation Scale. After treatment of major depression with Paroxetyna decrease of number of points in Hamilton Scale accounted for 90.6% (light depression), 64.1% (medium depression) and 57.4% (major depression). After treatment with Paroxetyna 47.47% patients noted full and fixed remission of the major depression syndrome, 6.06% of patients noted significant improvement, 20.20% noted medium improvement and 6.06% noted only poor improvement in major depression disease. Based on Montgomery-Asberg Scale approximately 47% patients noted full and fixed remission of the major depression syndrome, 6% of patients noted significant improvement, 20% noted medium improvement and 6% noted only poor improvement in major depression disease. The improvement was noted for the significant share of 80% of all patients treated with Paroxetyna. The treatment resulted in average decrease of number of points in Hamilton Depression Evaluation Scale from 46.2 points to 17.4 points. In the light depression syndrome the treatment with Paroxetyna resulted in the remission of 90.6% of the depression symptoms in Hamilton Depression Evaluation Scale and 91.2% of the depression symptoms in Beck Depression Self-Assessment Inventory.

Palabras clave : major depression; therapeutic effects; paroxetine; Sulpiride.